<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155323</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0926</org_study_id>
    <secondary_id>DISP-523</secondary_id>
    <nct_id>NCT01155323</nct_id>
  </id_info>
  <brief_title>Two Week Cross-Over Study Comparing Two Daily Disposable Contact Lenses</brief_title>
  <official_title>Proclear 1 Day Lens vs 1-Day Acuvue Moist Daily Disposable Contact Lens Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson K.K. Medical Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Visioncare Research Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <brief_summary>
    <textblock>
      This study seeks to evaluate and compare the clinical performance of two daily disposable
      soft contact lenses, Proclear 1 Day and 1-Day Acuvue Moist.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2010</start_date>
  <completion_date type="Actual">June 1, 2010</completion_date>
  <primary_completion_date type="Actual">June 1, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Rating of Comfort</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <description>This outcome is a weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision Quality</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <description>This outcome is a weighted combined score calculated from individual vision-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Rating of Handling</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <description>This outcome is a weighted combined score calculated from individual lens handling-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <description>Investigator assessment of the corneal staining. Staining is an indication of dryness on areas on the cornea. Here it is measured over 5 regions of the cornea: central, temporal, nasal, inferior, and superior. The staining is graded using the National Eye Institute (NEI)0-3 scale: grade 0 = normal, grade 1 = mild, grade 2 = moderate, grade 3 = severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Rating of Quality Perceptions</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <description>This outcome is a weighted combined score calculated from individual quality perception-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limbal Hyperemia</measure>
    <time_frame>after 1 week of wear</time_frame>
    <description>This outcome is assessed by the investigator during biomicroscopy examination using the following 0-4 scale: 0 = none, 1 = trace, 2 = mild, 3= moderate, 4 = severe.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>etafilcon A/omafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etafilcon A contact lenses will be worn during the first week and omafilcon A contact lenses will be worn during the second. Lenses were replaced daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omafilcon A/etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omafilcon A contact lenses will be worn during the first week and etafilcon A contact lenses will be worn during the second. Lenses were replaced daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A</intervention_name>
    <description>1-day soft contact lens</description>
    <arm_group_label>etafilcon A/omafilcon A</arm_group_label>
    <arm_group_label>omafilcon A/etafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>omafilcon A</intervention_name>
    <description>1-day soft contact lens</description>
    <arm_group_label>etafilcon A/omafilcon A</arm_group_label>
    <arm_group_label>omafilcon A/etafilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age and no more than 39 years of age

          -  Existing soft contact lens wearers

          -  Willing to signed a written Informed Consent.

          -  Own a mobile phone and are willing to receive and reply to Short Message Service (SMS)
             messages during the day.

          -  Have a contact lens spherical distance requirement between -1.00 diopters (D) and
             -6.00 diopters (D) in both eyes.

          -  Have an Astigmatism of 1.00D or less in both eyes.

          -  Require a visual correction in both eyes.

          -  Be correctable to a visual acuity of 6/9 (20/30) or better in each eye.

          -  Have normal eyes with no evidence of abnormality or disease that would preclude lens
             wear.

        Exclusion Criteria:

          -  Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, tarsal
             abnormalities, bulbar infection, or any other abnormality of the cornea that would
             contraindicate contact lens wear.

          -  Clinically significant corneal staining (Grade 3 in more than one region).

          -  Keratoconus or other corneal irregularity.

          -  Abnormal lachrymal secretions.

          -  Extended wear of contact lenses last 3 months.

          -  Polymethyl methacrylate (PMMA) or rigid gas-permeable (RGP) lens wear in the previous
             8 weeks.

          -  Refractive surgery.

          -  Eye injury/surgery within 8 weeks immediately prior to enrollment for this study.

          -  Pre-existing ocular irritation that would preclude contact lens fitting.

          -  Require concurrent ocular medication

          -  Any systemic illness which would contraindicate lens wear or the medical treatment of
             which would affect vision or successful lens wear.

          -  Any infectious disease (e.g., hepatitis, tuberculosis) or any immunosuppressive
             disease (e.g., HIV).

          -  Diabetes.

          -  Pregnant, lactating or planning a pregnancy at the time of enrollment.

          -  Participation in any concurrent clinical trial or in last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danny Sim, Diploma in Optometry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore Polytechnic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore Plytechnic</name>
      <address>
        <city>Singapore</city>
        <zip>139651</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <results_first_submitted>August 29, 2011</results_first_submitted>
  <results_first_submitted_qc>August 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2011</results_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etafilcon A/Omafilcon A</title>
          <description>etafilcon A contact lenses will be worn first and omafilcon A contact lenses will be worn second.</description>
        </group>
        <group group_id="P2">
          <title>Omafilcon A/Etafilcon A</title>
          <description>omafilcon A contact lenses will be worn first and etafilcon A contact lenses will be worn second.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Number of Participants</title>
          <description>This represents all subjects that completed the study minus one additional subject excluded due the discovery after study completion that the subject conflicted with exclusion criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Rating of Comfort</title>
        <description>This outcome is a weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <population>The analysis population represents subjects that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of Comfort</title>
          <description>This outcome is a weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
          <population>The analysis population represents subjects that completed the study per protocol.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="0.09"/>
                    <measurement group_id="O2" value="3.32" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis was that etafilcon A would be superior to omafilcon A for comfort.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
            <estimate_desc>Mean difference is calculated as etafilcon A minus omafilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vision Quality</title>
        <description>This outcome is a weighted combined score calculated from individual vision-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <population>The analysis population represents subjects that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision Quality</title>
          <description>This outcome is a weighted combined score calculated from individual vision-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
          <population>The analysis population represents subjects that completed the study per protocol.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="0.08"/>
                    <measurement group_id="O2" value="3.50" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis was that etafilcon A would be non-inferior to omafilcon A for vision.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -0.50</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as etafilcon A minus omafilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Rating of Handling</title>
        <description>This outcome is a weighted combined score calculated from individual lens handling-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <population>The analysis population represents subjects that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of Handling</title>
          <description>This outcome is a weighted combined score calculated from individual lens handling-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
          <population>The analysis population represents subjects that completed the study per protocol.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="0.09"/>
                    <measurement group_id="O2" value="3.48" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis was that etafilcon A would be non-inferior to omafilcon A for lens handling.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -0.50</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as etafilcon A minus omafilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Staining</title>
        <description>Investigator assessment of the corneal staining. Staining is an indication of dryness on areas on the cornea. Here it is measured over 5 regions of the cornea: central, temporal, nasal, inferior, and superior. The staining is graded using the National Eye Institute (NEI)0-3 scale: grade 0 = normal, grade 1 = mild, grade 2 = moderate, grade 3 = severe.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <population>The analysis population represents subjects that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining</title>
          <description>Investigator assessment of the corneal staining. Staining is an indication of dryness on areas on the cornea. Here it is measured over 5 regions of the cornea: central, temporal, nasal, inferior, and superior. The staining is graded using the National Eye Institute (NEI)0-3 scale: grade 0 = normal, grade 1 = mild, grade 2 = moderate, grade 3 = severe.</description>
          <population>The analysis population represents subjects that completed the study per protocol.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.01"/>
                    <measurement group_id="O2" value="0.09" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis was that etafilcon A would be equivalent to omafilcon A for corneal staining.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Margin = +/-0.50</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as etafilcon A minus omafilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Rating of Quality Perceptions</title>
        <description>This outcome is a weighted combined score calculated from individual quality perception-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <population>The analysis population represents subjects that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of Quality Perceptions</title>
          <description>This outcome is a weighted combined score calculated from individual quality perception-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response.</description>
          <population>The analysis population represents subjects that completed the study per protocol.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="0.08"/>
                    <measurement group_id="O2" value="3.44" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis was that etafilcon A would be non-inferior to omafilcon A for quality perceptions.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -0.50</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as etafilcon A minus omafilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Limbal Hyperemia</title>
        <description>This outcome is assessed by the investigator during biomicroscopy examination using the following 0-4 scale: 0 = none, 1 = trace, 2 = mild, 3= moderate, 4 = severe.</description>
        <time_frame>after 1 week of wear</time_frame>
        <population>The analysis population represents subjects that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
            <description>soft contact lens replaced daily, worn for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Limbal Hyperemia</title>
          <description>This outcome is assessed by the investigator during biomicroscopy examination using the following 0-4 scale: 0 = none, 1 = trace, 2 = mild, 3= moderate, 4 = severe.</description>
          <population>The analysis population represents subjects that completed the study per protocol.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.02"/>
                    <measurement group_id="O2" value="0.48" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis was that etafilcon A would be equivalent to omafilcon A from limbal hyperemia.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Margin = +/- 0.50</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as etafilcon A minus omafilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etafilcon A</title>
          <description>soft contact lens replaced daily, worn for one week.</description>
        </group>
        <group group_id="E2">
          <title>Omafilcon A</title>
          <description>soft contact lens replaced daily, worn for one week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may not be published or publicly presented without prior written approval of the sponsor. If the investigator wishes to publish or present any study findings, investigator shall contact sponsor to discuss publication plan.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wakana Katabami</name_or_title>
      <organization>Johnson and Johnson K.K.</organization>
      <phone>81-34411-8040 ext 22025</phone>
      <email>wkatabam@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

